NADMED has been selected to join the prestigious AMPlify program, a U.S. market entry initiative jointly organized by Mayo Clinic and Business Finland. The program combines world-class clinical expertise, valuable market knowledge, and extensive networks to support the growth of a select group of Finnish healthtech companies.
For NADMED, participation in AMPlify marks an important milestone as we take our next steps in the U.S. market. The program will open new opportunities for NADMED’s groundbreaking method to measure redox metabolites from any biological sample.
By delivering real-time insights into human metabolism, NADMED empowers physicians, researchers, and patients to better understand disease mechanisms, monitor therapeutic interventions, and promote healthy longevity.